{"result": "(\"entity\"<|>GLUCOSA<|>PERSON<|>Glucose is the main energy source for neoplastic cells, which may influence tumor growth.)\n##\n(\"entity\"<|>GLUTAMINA<|>PERSON<|>Glutamine is an amino acid that has shown improvement in postoperative complication rates when added to nutritional support.)\n##\n(\"entity\"<|>TRASPLANTE DE MÉDULA ÓSEA<|>EVENT<|>Bone marrow transplant procedure that may require parenteral nutrition for patients.)\n##\n(\"entity\"<|>ADENOCARCINOMAS INTRAABDOMINALES<|>EVENT<|>Advanced intra-abdominal adenocarcinomas that may necessitate specialized nutritional support.)\n##\n(\"relationship\"<|>GLUCOSA<|>PACIENTES CON CÁNCER<|>Glucose is a critical energy source for cancer patients, influencing their nutritional needs<|>7)\n##\n(\"relationship\"<|>GLUTAMINA<|>PACIENTES CON CÁNCER<|>Glutamine supplementation has been shown to improve outcomes in cancer patients requiring nutritional support<|>8)\n##\n(\"relationship\"<|>TRASPLANTE DE MÉDULA ÓSEA<|>PACIENTES CON CÁNCER<|>Patients undergoing bone marrow transplants often require parenteral nutrition<|>9)\n##\n(\"relationship\"<|>ADENOCARCINOMAS INTRAABDOMINALES<|>PACIENTES CON CÁNCER<|>Patients with advanced intra-abdominal adenocarcinomas may have specific nutritional requirements<|>8)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: periodo prolongado.\n\nLa NP puede administrarse por vía periférica si se to-\nlera un aporte hídrico elevado o si se emplea como re-\nfuerzo de otro tipo de nutrición. Para soportes nutri-\ncionales que se prolonguen más de una semana, es\npreferible la utilización de accesos centrales.\n\nAunque existen fórmulas comerciales, se debe formu-\nlar la composición de forma individualizada, para adap-\ntarnos a las necesidades del paciente. Debido a que la\nglucosa es la fuente energética principal para las células\nneoplásicas, algunos autores han postulado que podría\nfavorecer el crecimiento tumoral y que, por tanto, se\npodría considerar un aumento del aporte lipídico y una\ndisminución del aporte de glucosa en la fórmula paren-\nteral. Sin embargo, los estudios que se han hecho no\nson concluyentes, por lo que en el momento actual no\nexiste evidencia para apoyar una formulación específica\npara pacientes con cáncer40.\n\nEn pacientes quirúrgicos con indicaciones de sopor-\nte parenteral, la adición de glutamina a la nutrición,\nha demostrado una mejoría en la tasa de complicacio-\nnes postoperatorias, por lo que se puede considerar su\nadición en aquellos pacientes que precisan soporte\nparenteral. También en pacientes que van a someterse\na trasplante de médula ósea y que precisen parenteral,\nha demostrado una disminución en la tasa de infeccio-\nnes, aunque no del tiempo de ingreso. En ninguno de\nlos dos grupos de pacientes ha demostrado efectos\npositivos sobre la supervivencia.\n\nEstudios realizados en pacientes con adenocarcinomas\nintraabdominales avanzados (en los años 80) indicaban\n---\n650      BLOQUE: NUTRICIÓN EN ONCOLOGÍA\n\nque en pacientes que precisen nutrición parenteral, las fórmulas enriquecidas con aminoácidos ramificados podrían suponer una ventaja frente a las estándar para la síntesis de albúmina y el nivel de proteínas41. Ninguna de las guías clínicas actuales recomienda aminoácidos especiales en la nutrición parenteral de pacientes oncológicos, aunque se precisan estudios para esclarecer si existirían necesidades especiales.\n\n### 6.5.4. Nutrición artificial domiciliaria\n\nEl tratamiento nutricional debe interferir lo menos posible en la actividad habitual del paciente y para ello es muy importante que no suponga un alejamiento de su medio.\n\nAnte la posibilidad de realizar un soporte nutricional, debemos tener en cuenta los siguientes aspectos:\n\n- La adecuada tolerancia al soporte nutricional, que debe contribuir a mejorar la calidad de vida.\n- La situación clínica del paciente, que sea estable para poder permanecer fuera del medio hospitalario.\n- Colaboración en el medio familiar, para la administración del tratamiento, la detección de complicaciones y tener los conocimientos para resolverlas o para derivar al paciente a su equipo de nutrición cuando no sea posible solventar los problemas en el domicilio.\n\nLas guías de práctica clínica para el uso de nutrición parenteral domiciliaria (NPD) en pacientes con cáncer en estadios terminales, recomiendan instituir NPD en aquellos pacientes en los que el pronóstico de supervivencia es al menos de meses y que se espera mantengan NP al menos 6 semanas, siempre que la vía enteral no sea posible, que exista un beneficio potencial con la administración de NPD y que el paciente tenga una buena calidad de vida y soporte familiar27, 42.\n\n## 6.6. Soporte nutricional en situaciones especiales\n\n### 6.6.1. Cirugía: Enhanced recovery after surgery (ERAS)43\n\nLa ESPEN recomienda aplicar el protocolo ERAS en todos los pacientes oncológicos que vayan a ser sometidos a tratamiento quirúrgico, ya sea con intención curativa o paliativa. De acuerdo con este protocolo, todos los pacientes deben ser valorados para evaluar el estado nutricional y en aquellos en riesgo se debe ofertar el soporte nutricional adecuado. El protocolo ERAS persigue minimizar el estrés quirúrgico, mantener el estado nutricional, reducir las complicaciones y acortar los tiempos de recuperación. Para esto propone, minimizar el uso de opiáceos, la movilización precoz, mantener el tracto digestivo funcionante y si es posible optar por cirugías mínimamente invasivas. El componente nutricional del protocolo ERAS se basa en evitar el ayuno, emplear cargas de carbohidratos preoperatorias y reinstaurar la dieta oral el primer día del postoperatorio.\n\nA continuación recogemos algunos de los aspectos más relevantes de este protocolo:\n\n#### Pre-operatorio\n\nSe permite la ingesta de sólidos hasta 6 horas antes de la inducción anestésica y de líquidos claros hasta 2 horas antes en pacientes sin riesgo de aspiración (grado de\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>NUTRICIÓN PARENTERAL<|>EVENT<|>Nutritional support provided intravenously to patients who cannot eat by mouth, particularly in oncology settings.)\n##\n(\"entity\"<|>PACIENTES CON CÁNCER<|>PERSON<|>Patients diagnosed with cancer who may require specialized nutritional support.)\n##\n(\"entity\"<|>ESPEN<|>ORGANIZATION<|>The European Society for Clinical Nutrition and Metabolism, which provides guidelines for nutritional support in clinical settings.)\n##\n(\"entity\"<|>PROTOCOLO ERAS<|>EVENT<|>Enhanced Recovery After Surgery protocol aimed at improving recovery outcomes for surgical patients, particularly in oncology.)\n##\n(\"relationship\"<|>ESPEN<|>NUTRICIÓN PARENTERAL<|>ESPEN provides guidelines for the use of parenteral nutrition in clinical settings, especially for cancer patients<|>8)\n##\n(\"relationship\"<|>PACIENTES CON CÁNCER<|>NUTRICIÓN PARENTERAL<|>Cancer patients often require parenteral nutrition when they cannot meet their nutritional needs through oral intake<|>9)\n##\n(\"relationship\"<|>PROTOCOLO ERAS<|>NUTRICIÓN PARENTERAL<|>The ERAS protocol includes recommendations for nutritional support to enhance recovery in surgical patients<|>7)\n##\n(\"relationship\"<|>ESPEN<|>PROTOCOLO ERAS<|>ESPEN recommends the ERAS protocol for nutritional management in surgical oncology patients<|>6)\n<|COMPLETE|>"}]}